These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 33039794

  • 41. The tumor immune contexture of salivary duct carcinoma.
    Schvartsman G, Bell D, Rubin ML, Tetzlaff M, Hanna E, Lee JJ, Weber R, Phan J, Glisson BS, Ferrarotto R.
    Head Neck; 2021 Apr; 43(4):1213-1219. PubMed ID: 33576119
    [Abstract] [Full Text] [Related]

  • 42. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
    Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS.
    Head Neck; 2007 Oct; 29(10):907-12. PubMed ID: 17563907
    [Abstract] [Full Text] [Related]

  • 43. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.
    Nakaguro M, Tada Y, Faquin WC, Sadow PM, Wirth LJ, Nagao T.
    Cancer Cytopathol; 2020 Oct; 128(10):693-703. PubMed ID: 32421944
    [Abstract] [Full Text] [Related]

  • 44. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma.
    Piao S, Zhao S, Guo F, Xue J, Yao G, Wei Z, Huang Q, Sun Y, Zhang B.
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):627-35. PubMed ID: 22215147
    [Abstract] [Full Text] [Related]

  • 45. Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.
    Beck ACC, Lohuis PJFM, Al-Mamgani A, Smit LA, Klop WMC.
    Eur Arch Otorhinolaryngol; 2018 Jul; 275(7):1885-1892. PubMed ID: 29785551
    [Abstract] [Full Text] [Related]

  • 46. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
    Yamamoto H, Uryu H, Segawa Y, Tsuneyoshi M.
    Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
    [Abstract] [Full Text] [Related]

  • 47. Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares.
    Villepelet A, Lefèvre M, Verillaud B, Janot F, Garrel R, Vergez S, Bertolus C, Malard O, de Gabory L, Mauvais O, Baujat B, REFCOR membersRéseau d'Expertise Français des Cancers ORL Rares: (REFCOR, French Rare Head and Neck Cancer Expert Network): S. Albert, G. Andry, E. Babin, C. Bach, J.-M. Badet, C. Badoual, A.C. Baglin, A. Banal, B. Barry, E. Baudin, B. Baujat, R.J. Bensadoun, C. Bertolus, J.-P. Bessède, D. Blanchard, C. Borel, A. Bozorg-Grayeli, R. Breheret, P. Breton, L. Brugel, G. Calais, O. Casiraghi, E. Cassagnau, L. Castillo, P. Ceruse, F. Chabolle, D. Chevalier, J.C. Chobaut, O. Choussy, A. Cosmidis, A. Coste, V. Costes, L. Crampette, V. Darrouzet, P. Demez, P. Dessi, B. Devauchelle, G. Dolivet, F. Dubrulle, S. Duflo, X. Dufour, S. Faivre, N. Fakhry, C. Ferron, F. Floret, L. de Gabory, R. Garrel, L. Geoffrois, L. Gilain, A. Giovanni, A. Girod, B. Guerrier, S. Hans, P. Herman, P. Hofman, M. Housset, R. Jankowski, F. Jegoux, M. Juliéron, M.-C. Kaminsky, F. Kolb, J. Lacau St Guily, L. Laccoureye, B. Lallemant, P. Lang, E. Lartigau, J.-P. Lavieille, M. Lefevre, X. Leroy, O. Malard, F. Massip, O. Mauvais, J.-C. Merol, J. Michel, T. Mom, S. Morinière, E. de Monès, G. Moulin, G. Noel, G. Poissonnet, J.-M. Prades, D. de Raucourt, E. Reyt, C. Righini, Y. Marie Robin, F. Rolland, B. Ruhin, N. Sarroul, P. Schultz, E. Serrano, O. Sterkers, V. Strunski, A. Sudaka, M. Tassart, S. Testelin, J. Thariat, A. Timochenko, B. Toussaint, E. Uro Coste, G. Valette, T. Van den Abbeele, A. Varoquaux, F. Veillon, S. Vergez, M. Wassef..
    Head Neck; 2019 Mar; 41(3):584-591. PubMed ID: 30421824
    [Abstract] [Full Text] [Related]

  • 48. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
    Grünewald I, Trautmann M, Busch A, Bauer L, Huss S, Schweinshaupt P, Vollbrecht C, Odenthal M, Quaas A, Büttner R, Meyer MF, Beutner D, Hüttenbrink KB, Wardelmann E, Stenner M, Hartmann W.
    Oncotarget; 2016 Nov 15; 7(46):75261-75272. PubMed ID: 27662657
    [Abstract] [Full Text] [Related]

  • 49. Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.
    Kawakita D, Tada Y, Imanishi Y, Beppu S, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Shimizu A, Sato Y, Fushimi C, Takase S, Okada T, Sato H, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Shimura T, Hanazawa T, Murakami S, Nagao T.
    Oncotarget; 2017 Jan 03; 8(1):1083-1091. PubMed ID: 27894101
    [Abstract] [Full Text] [Related]

  • 50. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy.
    Kessel K, Seifert R, Weckesser M, Roll W, Humberg V, Schlack K, Bögemann M, Bernemann C, Rahbar K.
    Theranostics; 2020 Jan 03; 10(17):7645-7655. PubMed ID: 32685010
    [Abstract] [Full Text] [Related]

  • 51. The Characteristics and Prognostic Effect of E-Cadherin Expression in Colorectal Signet Ring Cell Carcinoma.
    Wang R, Ma X, Li Y, He Y, Huang D, Cai S, Peng J.
    PLoS One; 2016 Jan 03; 11(8):e0160527. PubMed ID: 27509205
    [Abstract] [Full Text] [Related]

  • 52. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
    Neuzillet C, Couvelard A, Tijeras-Raballand A, de Mestier L, de Gramont A, Bédossa P, Paradis V, Sauvanet A, Bachet JB, Ruszniewski P, Raymond E, Hammel P, Cros J.
    Histopathology; 2015 Nov 03; 67(5):664-76. PubMed ID: 25809563
    [Abstract] [Full Text] [Related]

  • 53. Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization.
    Choi J, Lee HE, Kim MA, Jang BG, Lee HS, Kim WH.
    PLoS One; 2014 Nov 03; 9(11):e111658. PubMed ID: 25364819
    [Abstract] [Full Text] [Related]

  • 54. [Expression and significance of E-cadherin in adenoid cystic carcinoma of the salivary glands].
    Lai FY, Zhang Q, Wu QL, Qing J, Cao Y.
    Ai Zheng; 2007 Sep 03; 26(9):1025-8. PubMed ID: 17927866
    [Abstract] [Full Text] [Related]

  • 55. N-cadherin and P-cadherin are biomarkers for invasion, metastasis, and poor prognosis of gallbladder carcinomas.
    Yi S, Yang ZL, Miao X, Zou Q, Li J, Liang L, Zeng G, Chen S.
    Pathol Res Pract; 2014 Jun 03; 210(6):363-8. PubMed ID: 24636838
    [Abstract] [Full Text] [Related]

  • 56. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ.
    Götte M, Kersting C, Radke I, Kiesel L, Wülfing P.
    Breast Cancer Res; 2007 Jun 03; 9(1):R8. PubMed ID: 17244359
    [Abstract] [Full Text] [Related]

  • 57. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type.
    Hsieh MS, Lee YH, Jin YT, Kuo YJ.
    Virchows Arch; 2020 Oct 03; 477(4):581-592. PubMed ID: 32383006
    [Abstract] [Full Text] [Related]

  • 58. Parotid salivary duct carcinoma: a single institution's 20-year experience.
    Stodulski D, Mikaszewski B, Majewska H, Kuczkowski J.
    Eur Arch Otorhinolaryngol; 2019 Jul 03; 276(7):2031-2038. PubMed ID: 31062093
    [Abstract] [Full Text] [Related]

  • 59. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
    Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T.
    Cancer; 2005 Jun 15; 103(12):2526-33. PubMed ID: 15900577
    [Abstract] [Full Text] [Related]

  • 60. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
    Zhao L, Niu F, Shen H, Liu X, Chen L, Niu Y.
    Virchows Arch; 2016 Jun 15; 468(6):687-96. PubMed ID: 27026268
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.